Stein Robert Benjamin
Known title: EVP, Research and DevelopmentCIK: 0001597158
Associated companies
Transaction History
| MDXG | ▼ Sell | Open Market | 10,365 | $62K | 5/16/2023 | View on chart |
| MDXG | ▼ Sell | Open Market | 3,607 | $22K | 5/15/2023 | View on chart |
| MDXG | ▼ Sell | Open Market | 5,869 | $35K | 5/10/2023 | View on chart |
| MDXG | ▼ Sell | Open Market | 51,756 | $276K | 5/4/2023 | View on chart |
| MDXG | ▼ Sell | Open Market | 5,987 | $22K | 4/25/2023 | View on chart |
| MDXG | ▼ Sell | Open Market | 5,996 | $20K | 4/11/2023 | View on chart |
| MDXG | ▲ Buy | Grant | 135,065 | $624K | 3/13/2023 | View on chart |
| MDXG | ▼ Sell | Open Market | 12,355 | $52K | 3/7/2023 | View on chart |
| MDXG | ▼ Sell | Open Market | 8,329 | $29K | 9/13/2022 | View on chart |
| MDXG | ▼ Sell | Open Market | 19,000 | $65K | 9/12/2022 | View on chart |
| MDXG | ▼ Sell | Open Market | 8,503 | $34K | 8/12/2022 | View on chart |
| MDXG | ▼ Sell | Open Market | 19,500 | $71K | 8/4/2022 | View on chart |
| MDXG | ▼ Sell | Open Market | 14,600 | $51K | 6/28/2022 | View on chart |
| MDXG | ▲ Buy | Grant | 178,571 | $825K | 4/8/2022 | View on chart |
| MDXG | ▼ Sell | Open Market | 11,672 | $57K | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification
A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.